Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.19
Views: 914

Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA

Dr Peter Barth speaks to ecancer at the 2019 International Myeloma Workshop meeting in Boston about a study looking at the comparative effectiveness of lenalidomide, bortezomib (RVD), and their combination as firstline treatment of older patients with myeloma.

He explains that it is widely known that triplet induction therapies for multiple myeloma are much more effective than doublet therapies but that in elderly patients this hasn't really been studied.

Dr Barth reports that retrospectively looking at data and using a propensity score analysis showed that patients receiving triplet therapy had a longer time to treatment failure and overall survival compared to those receiving a doublet therapy.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation